Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,030.00 at TD Cowen

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price boosted by TD Cowen from $1,020.00 to $1,030.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

REGN has been the subject of several other reports. Royal Bank of Canada reiterated an outperform rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Truist Financial reiterated a buy rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a report on Wednesday, March 13th. Cantor Fitzgerald reiterated a neutral rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. Finally, UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a buy rating in a research note on Wednesday, April 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $977.77.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $906.54 on Wednesday. Regeneron Pharmaceuticals has a 52 week low of $684.80 and a 52 week high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The stock has a market cap of $99.50 billion, a price-to-earnings ratio of 26.09, a price-to-earnings-growth ratio of 2.61 and a beta of 0.11. The company has a 50-day moving average price of $950.58 and a two-hundred day moving average price of $893.29.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the prior year, the firm earned $10.96 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals will post 38.8 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. FMR LLC increased its stake in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after purchasing an additional 669,517 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock worth $7,762,577,000 after purchasing an additional 39,780 shares during the last quarter. Capital World Investors increased its stake in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares during the last quarter. Putnam Investments LLC grew its stake in Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after buying an additional 24,329 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Regeneron Pharmaceuticals by 3.3% in the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after buying an additional 34,326 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.